Moderna and Merck's AI-Designed Personalized Cancer Vaccine Succeeds in Phase 3 Trial
TansuYegen · x · 2026-08-20
Moderna and Merck's personalized mRNA cancer vaccine achieved positive results in a Phase 3 trial.
- Mechanism: AI is used to sequence tumor DNA vs. healthy DNA, selecting mutations most likely to trigger a strong immune response to create a custom mRNA vaccine targeting up to 34 cancer-specific mutations per patient.
- Data: 5-year follow-up data shows a 68.8% cancer-free rate for the vaccine group, significantly higher than the 49.1% control group.
More from Research
- Logit lens on a Beat Saber finetune reveals it reuses language grammar circuits — ctjlewis · 2026-10-16
- Handwired compiles plain JavaScript into an exact, fully differentiable neural net — ctjlewis · 2026-10-16
- 128×128 record stands: how intermediate-work experiments foreshadowed reasoning models — ctjlewis · 2026-10-16
- TeamFusion: preference-based AI proxies debate to preserve minority views in team decisions — burkov · 2026-10-16
- MIT's C-GMT gives humanoid robots whole-body compliance without sacrificing motion tracking — MIT_CSAIL · 2026-10-16
- SUNY Albany to offer Topological Deep Learning course, from Perceptrons to WL test — burny_tech · 2026-10-16